Immunome
IMNM
35 hedge funds and large institutions have $19.7M invested in Immunome in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 9 closing their positions.
56% more call options, than puts
Call options by funds: $474K | Put options by funds: $304K
27% more capital invested
Capital invested by funds: $15.4M → $19.7M (+$4.23M)
3.42% more ownership
Funds ownership: 15.95% → 19.37% (+3.4%)
0% more funds holding
Funds holding: 35 → 35 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
Top Buyers
Top Sellers
IMNM Hedge Fund Activity: Q3 2023 in Review
35 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q3 2023, worth a combined $19.7M — up 27% from $15.4M a quarter earlier.
Fund positioning in IMNM was balanced in Q3 2023: 9 funds opened new positions, 9 closed out, 6 added to existing stakes and 10 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $1.28M. The largest seller was Cerity Partners, exiting entirely with an estimated $531K sold.
- 35 institutional investors held Immunome (IMNM) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $19.7M of Immunome stock for Q3 2023, up 27% quarter-over-quarter.
- 9 funds opened new Immunome positions in Q3 2023 and 9 closed out, a net change of 0 holders.
- The largest Immunome buyer in Q3 2023 was T. Rowe Price Associates, an estimated $1.28M added.
- The largest Immunome seller in Q3 2023 was Cerity Partners, an estimated $531K sold.
Based on aggregated 13F filings for Q3 2023.